Technical Analysis for RNAC - Cartesian Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 34.72 | 10.43% | 3.28 |
RNAC closed up 10.43 percent on Friday, May 31, 2024, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Jun 14
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Stochastic Reached Overbought | Strength | 10.43% | |
| Upper Bollinger Band Walk | Strength | 10.43% | |
| Multiple of Ten Bullish | Other | 10.43% |
| Alert | Time |
|---|---|
| Up 10% | 1 day ago |
| Up 1 ATR | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Up 5% | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/14/2024
Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company’s lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis, with additional Phase 2 studies planned in systemic lupus erythematosus as well as ocular autoimmune and vasculitic autoimmune basket trials. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.6 |
| 52 Week Low | 11.665 |
| Average Volume | 93,070 |
| 200-Day Moving Average | 26.09 |
| 50-Day Moving Average | 21.55 |
| 20-Day Moving Average | 25.79 |
| 10-Day Moving Average | 27.58 |
| Average True Range | 3.01 |
| RSI (14) | 79.47 |
| ADX | 39.58 |
| +DI | 40.37 |
| -DI | 8.63 |
| Chandelier Exit (Long, 3 ATRs) | 27.16 |
| Chandelier Exit (Short, 3 ATRs) | 29.54 |
| Upper Bollinger Bands | 32.15 |
| Lower Bollinger Band | 19.42 |
| Percent B (%b) | 1.2 |
| BandWidth | 49.36 |
| MACD Line | 2.55 |
| MACD Signal Line | 1.81 |
| MACD Histogram | 0.7339 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 42.39 | ||||
| Resistance 3 (R3) | 42.03 | 39.12 | 41.11 | ||
| Resistance 2 (R2) | 39.12 | 37.16 | 39.29 | 40.68 | |
| Resistance 1 (R1) | 36.92 | 35.96 | 38.02 | 37.28 | 40.26 |
| Pivot Point | 34.00 | 34.00 | 34.55 | 34.18 | 34.00 |
| Support 1 (S1) | 31.80 | 32.05 | 32.90 | 32.16 | 29.18 |
| Support 2 (S2) | 28.89 | 30.84 | 29.07 | 28.76 | |
| Support 3 (S3) | 26.69 | 28.89 | 28.33 | ||
| Support 4 (S4) | 27.05 |
